Heidelberg Pharma (Group)

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma. The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. *

	Start	2017-10-18 renamed
	Predecessor	Wilex (Group)
	Industry	cancer drug
	Industry 2	cancer test
	Person	Schmidt-Brand, Jan (Wilex 201404– CEO before CFO + Heidelberg Pharma 200109– CEO + CFO)
	Person 2	Wilhelm, Olaf Georg (Therawis 201405– Managing Director before Wilex 2001–201403 CEO)

	Region	Ladenburg
	Country	Germany
	Street	22 Gregor-Mendel-Str.
	City	68526 Ladenburg
		Address record changed: 2020-12-12

Basic data	Employees	C: 51 to 100 (2018-11-30)
	Currency	EUR
	Annual sales	4,373,456 (income, total, consolidated (2017/18) 2018-11-30)
	Profit	-11,671,980 (2018-11-30)
	Cash	19,440,352 (2018-11-30)

		* Document for ï¿½About Sectionï¿½: Heidelberg Pharma AG. (10/19/17). "Press Release: Wilex AG Successfully Completes Change of Name to Heidelberg Pharma AG". Ladenburg.

		Record changed: 2020-12-12

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Heidelberg Pharma (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)